DCDonna Cosgrove

Donna Cosgrove

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Donna Cosgrove has a total of 118 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Genes influenced by MEF2C contribute to neurodevelopmental disease via gene expression changes that affect multiple types of cortical excitatory neurons

    by Donna Cosgrove, Laura Whitton, Laura Fahey, Pilib Ó Broin, Gary Donohoe, Derek W Morris

    Myocyte enhancer factor 2 C (MEF2C) is an important transcription factor during neurodevelopment. Mutation or deletion of MEF2C causes intellectual disability (ID), and common variants within MEF2C are associated with cognitive function and schizophrenia risk. We investigated if genes influenced by MEF2C during neurodevelopment are enriched for genes associated with neurodevelopmental phenotypes and if this can be leveraged to identify biological mechanisms and individual brain cell types affected. We used a set of 1055 genes that were differentially expressed in the adult mouse brain following early embryonic deletion of Mef2c in excitatory cortical neurons. Using genome-wide association studies data, we found these differentially expressed genes (DEGs) to be enriched for genes associated with schizophrenia, intelligence and educational attainment but not autism spectrum disorder (ASD). For this gene set, genes that overlap with target genes of the Fragile X mental retardation protein (FMRP) are a major driver of these enrichments. Using trios data, we found these DEGs to be enriched for genes containing de novo mutations reported in ASD and ID, but not schizophrenia. Using single-cell RNA sequencing data, we identified that a number of different excitatory glutamatergic neurons in the cortex were enriched for these DEGs including deep layer pyramidal cells and cells in the retrosplenial cortex, entorhinal cortex and subiculum, and these cell types are also enriched for FMRP target genes. The involvement of MEF2C and FMRP in synapse elimination suggests that disruption of this process in these cell types during neurodevelopment contributes to cognitive function and risk of neurodevelopmental disorders.


  • Open Access

    Genes influenced by MEF2C contribute to neurodevelopmental disease via gene expression changes that affect multiple types of cortical excitatory neurons

    by Donna Cosgrove, Laura Whitton, Laura Fahey, Pilib Ó Broin, Gary Donohoe, Derek W. Morris

    Myocyte enhancer factor 2 C (MEF2C) is an important transcription factor during neurodevelopment. Mutation or deletion of MEF2C causes intellectual disability (ID) and common variants within MEF2C are associated with cognitive function and schizophrenia risk. We investigated if genes influenced by MEF2C during neurodevelopment are enriched for genes associated with neurodevelopmental phenotypes, and if this can be leveraged to identify biological mechanisms and individual brain cell types affected. We used a set of 1,052 genes that were differentially expressed in the adult mouse brain following early embryonic deletion of Mef2c in excitatory cortical neurons. Using GWAS data, we found these differentially expressed genes (DEGs) to be enriched for genes associated with schizophrenia, intelligence and educational attainment but not autism spectrum disorder (ASD). Using sequencing data from trios studies, we found these DEGs to be enriched for genes containing de novo mutations reported in ASD and ID, but not schizophrenia. Using single cell RNA-seq data, we identified that a number of different excitatory glutamatergic neurons in the cortex were enriched for these DEGs including deep layer pyramidal cells and cells in the retrosplenial cortex, entorhinal cortex and subiculum. These data indicate that genes influenced by MEF2C during neurodevelopment contribute to cognitive function and risk of neurodevelopmental disorders. Within excitatory neurons, common SNPs in these genes contribute to cognition and SZ risk via an effect on synaptic function based on gene ontology analysis. In contrast, rare mutations contribute to earlier onset ASD and ID via an effect on cell morphogenesis. Author Summary: Schizophrenia is a complex disorder caused by many genes. Current drugs for schizophrenia are only partially effective and do not treat cognitive deficits, which are key factors for explaining disability. Here we take an individual gene identified in genetic studies of schizophrenia and cognition called MEF2C , which on its own is a very important regulator of brain development. We use data from a mouse study where MEF2C has been stopped from functioning or knocked out during brain development. The effect of that knock out has been measured when the mice reach adulthood, in the form of a set of differentially expressed genes (DEGs) from the somatosensory cortex. We found that this set of DEGs contains more genes than expected by chance that are associated with schizophrenia and cognition or contain rare new ( de novo ) mutations reported in autism and intellectual disability. Using gene expression data from single brain cells, we identified that a number of specific excitatory glutamatergic neurons in the cortex were enriched for these DEGs. This study provides evidence that the molecular mechanisms that underpin schizophrenia and cognitive function include disruption of cell types influenced by MEF2C.


  • The Genetics of Endophenotypes of Neurofunction to Understand Schizophrenia (GENUS) consortium: A collaborative cognitive and neuroimaging genetics project

    by Gabriëlla A.M. Blokland, Elisabetta C. del Re, Raquelle I. Mesholam-Gately, Jorge Jovicich, Joey W. Trampush, Matcheri S. Keshavan, Lynn E. DeLisi, James T.R. Walters, Jessica A. Turner, Anil K. Malhotra, et al.


  • Open Access

    Cognitive Characterization of Schizophrenia Risk Variants Involved in Synaptic Transmission: Evidence of CACNA1C's Role in Working Memory

    by The Wellcome Trust Case Control Consortium, Donna Cosgrove, Omar Mothersill, Kimberley Kendall, Bettina Konte, Denise Harold, Ina Giegling, Annette Hartmann, Alex Richards, Kiran Mantripragada, et al.

    With >100 common variants associated with schizophrenia risk, establishing their biological significance is a priority. We sought to establish cognitive effects of risk variants at loci implicated in synaptic transmission by (1) identifying GWAS schizophrenia variants whose associated gene function is related to synaptic transmission, and (2) testing for association between these and measures of neurocognitive function. We selected variants, reported in the largest GWAS to date, associated with genes involved in synaptic transmission. Associations between genotype and cognitive test score were analyzed in a discovery sample (988 Irish participants, including 798 with psychosis), and replication samples (528 UK patients with schizophrenia/schizoaffective disorder; 921 German participants including 362 patients with schizophrenia). Three loci showed significant associations with neuropsychological performance in the discovery samples. This included an association between the rs2007044 (risk allele G) within CACNA1C and poorer working memory performance (increased errors B (95% CI)=0.635–4.535, p=0.012), an effect driven mainly by the psychosis groups. In an fMRI analysis of working memory performance (n=84 healthy participants, a subset of the discovery sample), we further found evidence that the same CACNA1C allele was associated with decreased functional connectivity between the right dorsolateral prefrontal cortex and right superior occipital gyrus/cuneus and anterior cingulate cortex. In conclusion, these data provide evidence to suggest that the CACNA1C risk variant rs2007044 is associated with poorer memory function that may result from risk carriers’ difficulty with top-down initiated responses caused by dysconnectivity between the right DLPFC and several cortical regions.


  • Open Access

    MiR-137-derived polygenic risk: effects on cognitive performance in patients with schizophrenia and controls

    by D Cosgrove, D Harold, O Mothersill, R Anney, M J Hill, N J Bray, G Blokland, T Petryshen, A Richards, K Mantripragada, et al.

    Variants at microRNA-137 (MIR137), one of the most strongly associated schizophrenia risk loci identified to date, have been associated with poorer cognitive performance. As microRNA-137 is known to regulate the expression of ~1900 other genes, including several that are independently associated with schizophrenia, we tested whether this gene set was also associated with variation in cognitive performance. Our analysis was based on an empirically derived list of genes whose expression was altered by manipulation of MIR137 expression. This list was cross-referenced with genome-wide schizophrenia association data to construct individual polygenic scores. We then tested, in a sample of 808 patients and 192 controls, whether these risk scores were associated with altered performance on cognitive functions known to be affected in schizophrenia. A subgroup of healthy participants also underwent functional imaging during memory (n=108) and face processing tasks (n=83). Increased polygenic risk within the empirically derived miR-137 regulated gene score was associated with significantly lower performance on intelligence quotient, working memory and episodic memory. These effects were observed most clearly at a polygenic threshold of P=0.05, although significant results were observed at all three thresholds analyzed. This association was found independently for the gene set as a whole, excluding the schizophrenia-associated MIR137 SNP itself. Analysis of the spatial working memory fMRI task further suggested that increased risk score (thresholded at P=10−5) was significantly associated with increased activation of the right inferior occipital gyrus. In conclusion, these data are consistent with emerging evidence that MIR137 associated risk for schizophrenia may relate to its broader downstream genetic effects.


  • Cognitive analysis of schizophrenia risk genes that function as epigenetic regulators of gene expression

    by Laura Whitton, Donna Cosgrove, Christopher Clarkson, Denise Harold, Kimberley Kendall, Alex Richards, Kiran Mantripragada, Michael J. Owen, Michael C. O'Donovan, James Walters, et al.

    Epigenetic mechanisms are an important heritable and dynamic means of regulating various genomic functions, including gene expression, to orchestrate brain development, adult neurogenesis, and synaptic plasticity. These processes when perturbed are thought to contribute to schizophrenia pathophysiology. A core feature of schizophrenia is cognitive dysfunction. For genetic disorders where cognitive impairment is more severe such as intellectual disability, there are a disproportionally high number of genes involved in the epigenetic regulation of gene transcription. Evidence now supports some shared genetic aetiology between schizophrenia and intellectual disability. GWAS have identified 108 chromosomal regions associated with schizophrenia risk that span 350 genes. This study identified genes mapping to those loci that have epigenetic functions, and tested the risk alleles defining those loci for association with cognitive deficits. We developed a list of 350 genes with epigenetic functions and cross‐referenced this with the GWAS loci. This identified eight candidate genes: BCL11B, CHD7, EP300, EPC2, GATAD2A, KDM3B, RERE, SATB2. Using a dataset of Irish psychosis cases and controls (n = 1235), the schizophrenia risk SNPs at these loci were tested for effects on IQ, working memory, episodic memory, and attention. Strongest associations were for rs6984242 with both measures of IQ (P = 0.001) and episodic memory (P = 0.007). We link rs6984242 to CHD7 via a long range eQTL. These associations were not replicated in independent samples. Our study highlights that a number of genes mapping to risk loci for schizophrenia may function as epigenetic regulators of gene expression but further studies are required to establish a role for these genes in cognition.


  • Greater number of older siblings is associated with decreased theory of mind ability in psychosis

    by Chita Murray, Donna Cosgrove, Aiden Corvin, Michael Gill, Derek W. Morris, Gary Donohoe

  • Open Access

    Polygenic scores from the MiR137 pathway explain variability in cognitive performance in patients with schizophrenia and controls.

    by Cosgrove Donna, Morris Derek, Anney Ric, Hargreaves April, Genomics Consortium Psychiatric, Gill Michael, Corvin Aiden, Donohoe Gary

    Introduction Genome-wide association studies have identified rs1622579, a common variant located within an intronic region of MiR137, as a risk variant for schizophrenia. MiR137 has a hypothesized role in neural cell proliferation, migration and maturation. Cognitively, this variant is associated with deficits in verbal episodic memory, and altered fronto-amygdala connectivity. As MiR137 interacts with several other genome wide associated variants (e.g. ZNF804A, TCF4, CACNA1C, CSMD1 and WBP1L), we tested whether these cognitive effects were associated with polygenic risk in a set of identified downstream targets of MiR137. Methodology Polygene scores were calculated by (1) selecting all identified downstream genetic targets of MiR137 (Hill et al., 2014); (2) selecting risk SNPs within each of these genes based on risk estimates from the Psychiatric Genomics Consortium (Ripke et al., 2011), and (3) ascribing a polygenic risk score to each participant based on the total number of risk alleles they carried. To define risk, we used 3 arbitrary p-value thresholds (p < 10-5, p < 0.05, and p < 0.5) from the PGC1 case-control analysis. To estimate these polygene effects on cognitive deficits associated with SZ (IQ, episodic and working memory, attention control, and theory of mind) linear regression analyses was performed, with age and gender entered as variables of no interest. We carried out three separate analyses: all cases and controls (n=586), patients with a broad diagnosis of psychosis including non-schizophrenia psychosis (n=489) and patients with schizophrenia and schizoaffective disorder (n=379). Results MiR137 polygenic risk scores were significantly higher in the broad and narrow diagnosis groups compared to the controls (F(2,1081) =5.52, p<0.01). Poorer performance on measures of IQ, memory, and attention were each found to be associated with higher MiR137 polygene scores thresholded at p=0.05, including paired associated learning (p<0.001); faces, letter-number sequencing (LNS) sustained attention to reaction time (SART) (p<0.01); full-scale IQ, logical memory (LM) and spatial working memory (SWM) (p<0.05). The amount of variance explained on the measures varied between 1% and 2.6% Discussion These data support a modest but significant influence of this MiR137 'pathway' on cognition, across multiple measures of cognition. These widespread cognitive effects are consistent with MiR137’s previously described role in brain development. Greater variance was explained when all cases and controls were included, rather than considering narrow, broad, and controls separately. Extending on previous findings, MiR137's effects on cognition were significantly more apparent when considered in combination with the other risk variants with which it interacts rather than when the rs1622579 risk variant was considered in isolation.